Prostate cancer is termed as a form of cancer that develops into the male reproductive system. The growth of prostate cancer is sluggish and unchanging but at times it can spread from prostate (gland) to other body parts including lymph and bone node. In the beginning prostate cancer do not show any indication but in extreme cases, it may cause a problem during sexual intercourse as well as may cause pain during urination. Castration-resistant prostate cancer is denoted as a prostate cancer that is spread to other body parts and is resistant to surgical or therapeutic treatment.

Risk factors associated with prostate cancer include medication exposure, genetic predisposition, and unhygienic diet. Diagnostic treatment for the detection of prostate cancer includes tumor marker, biopsy, staging test, and prostate imaging. The critical factor about castration resistant type of prostate cancer is that it is impervious to surgical as well as medical treatment. Other treatment options that are available for prostate cancer comprise antiangiogenic treatment, bone-targeted therapies, hormone therapy, and immune modulation.

Increasing prevalence of prostate cancer and rising demand for proper treatment is anticipated to bolster the market

The prostate cancer treatment market is majorly driven by high occurrence of prostate cancer across the world. Prostate cancer is estimated as the common cause of death among men in the U.S. According to the California Journal of Clinical Cancer, 2010, 217,730 men were diagnosed with prostate cancer suggesting that in the U.S. 1 in 6 U.S. men have received diagnosis test for prostate cancer at some point during their lifespan. Moreover, according to the National Centre for Biotechnology Information (NCBI) prevalence of prostate cancer is observed more in geriatric people (above 65 years of age). According to the World Health Organization (WHO), the global geriatric population is anticipated to reach approximately 2 billion by 2050. Moreover, the global geriatric population would grow at the fastest rate in developed countries such as the U.S., the U.K., and Japan. Thus, growing geriatric population and increasing demand for proper treatment is expected to further propel the global market significantly. Technological advancement in a diagnostic test for detection and treatment is also expected to drive the global prostate cancer treatment market.

However, lack of proper healthcare infrastructure and lack of awareness present in few developing and middle-income economies might hinder the growth of global prostate cancer treatment market.

Global Prostate Cancer Treatment Market Taxonomy:

The global prostate cancer treatment market is segmented on the basis of treatment therapy and geography.

On the basis of treatment therapy, the global prostate cancer treatment market is segmented into:

• Chemotherapy
  • Systemic Therapy
  • Regional Chemotherapy
• Hormonal Therapy
  • Anti-Androgens
  • LHRH Antagonists
  • LHRH Analogs
• Targeted Therapy
  • Apoptosis inducing drugs
  • Angiogenesis inhibitor
  • Signal transduction inhibitor
• Immunotherapy
  • Vaccines

On the basis of geography, the global prostate cancer treatment market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Growing obtainability of diverse treatment opportunities to make significant market growth in the Asia Pacific region

In terms of geography, currently North America region is estimated to dominate the global prostate cancer treatment market. High occurrence and high death rate of prostate cancer in the U.S. are the principal reasons accountable for the governance of North America Prostate Cancer Treatment market. In addition, high investment in R&D, rising government support for the development of newer immunotherapies and targeted drug therapies to treat such cancer is also anticipated to boost the prostate cancer treatment market in North America.

However, the Asia Pacific Prostate Cancer Treatment Market is anticipated to grow significantly during the forecast period. Rising awareness of prostate cancer cases and increasing demand for appropriate treatment is anticipated to bolster the prostate cancer treatment market in Asia Pacific region. In addition, governments of various countries in this region are playing a dynamic part to create awareness through online portals and programs that is anticipated to enhance the market growth significantly. Moreover, improving healthcare infrastructure, growing investments & adoption of new technologies by key players, and development of immunotherapies & targeted therapies, are creating a strong pipeline for further growth of this market in Asia Pacific region.

Key players in global prostate cancer treatment market:

• Pfizer Inc.
• Amgen
• Janssen Biotech Inc.
• AstraZeneca Pharmaceuticals
• AbbVie
• Sanofi Aventis